|Description||ILK-IN-1, a ILK inhibitor, has been found to restrain the tumor cell growth through regulating signaling pathways related to oncogenesis and tumor progression. IC50: 0.6 μM.|
|Synonyms||ILK-IN-1; CHEMBL1830587; GTPL8116; SCHEMBL8536228; BDBM50353484; CS-4936|
|Solubility||10 mM in DMSO|
|Application||ILK-IN-1 is a ILK inhibitor that has been found to restrain the tumor cell growth through regulating signaling pathways related to oncogenesis and tumor progression.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
ATN-161 trifluoroacetate salt
ATN-161 trifluoroacetate salt is a beta integrin antagonist with antitumor activity. It is a five -amino-acid peptide derived from the synergy region of fibrone...
BIO 5192 is a selective and potent inhibitor of integrin α4β1 (Very Late Antigen-4; VLA-4) (Kd < 10 pM) wth selectivity for α4β1 over a range of other integrins...
R-BC154, a high affinity fluorescent α4β1/α9β1 integrin antagonist (Kd= 12.7 and 38 nM, respectively), was based on a series of N-phenylsulfonyl proline dipepti...
TCS 2314 is an integrin very late antigen-4 (VLA-4; α4β1) antagonist (IC50 = 4.4 nM) that inhibits the activation of inflammatory cells.
BIO 1211 is a selective and high affinity integrin α4β1 (Very Late Antigen 4; VLA-4) inhibitor with 200-fold selectivity for the activated form of α4β1 (KD = 70...
Echistatin, α1 isoform
Echistatin, α1 isoform is a potent and irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). It exhibits inhibitory activity for bone reabsorption (IC50 = 0.1 n...
P11 is a potent antagonist of the integrin αvβ3-vitronectin interaction with IC50 value of 25.72 nM.
Obtustatin is an integrin α1β1 inhibitor with IC50 value of 0.8 nM for α1β1 binding to type IV collagen. Some research shows that it has antitumor efficacy in a...
ILK-IN-1, a ILK inhibitor, has been found to restrain the tumor cell growth through regulating signaling pathways related to oncogenesis and tumor progression. ...
Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals for the treatment of ulcerative colitis and Crohn's disease under the trade name En...
Tirofiban hydrochloride monohydrate
Tirofiban is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Tirofiban is an antithrombotic used in the treatment of unstable angina...
SR121566A, a non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, has been shown to block platelet aggregation induced by a wide variety of agonists incl...
ALG1001, also known as Luminate, a first-in-class integrin peptide therapy, is an angiogenesis inhibitors and Integrin alpha 5 beta 1 modulator. A study from Jo...
TC-I 15 is a potent α2β1 integrin inhibitor (IC50 = 12 and 715 nM for the inhibition of human platelet adhesion to type I collagen and for platelets under stati...
TR14035 blocked the binding of human alpha(4)beta(7) to an (125)I-MAdCAM-Ig fusion protein with IC(50) values of 0.75 nM. TR14035 blocked binding of human alpha...
Zaurategrast is an oral α4-integrin inhibitor. It significantly decreased the capacity of lymphocytes to bind vascular adhesion molecule-1 (VCAM-1) and the expr...
ATN-161 is a small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for i...
BTT 3033 is a selective inhibitor of α2β1 integrin (EC50 = 130 nM for α2β1 binding to collagen I) that binds to the α2I domain. BTT 3033 inhibits platelet aggre...
Leukadherin-1, also known as LA1, is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1. Leukadherin-1 suppresses hu...
RWJ 50271 is a selective inhibitor of LFA-1/ICAM-1 mediated cell adhesion (sICAM) (IC50= 5 μM in HL60 cells).